How Long Do Semaglutide Side Effects Last?

Semaglutide, a medication used in weight management, has given hope to many looking for effective obesity treatments. With the rise in obesity rates and the demand for sustainable weight loss solutions, semaglutide stands out for its efficacy. This has been supported by numerous trials, including studies on its once-weekly administration in adults with obesity. (1) But, as with many powerful medications, understanding its side effects is critical for those considering or starting treatment.

Introduction to Semaglutide for Weight Loss

Semaglutide belongs to the class of medications known as GLP-1 receptor agonists. It mimics a hormone that slows gastric emptying and targets areas of the brain involved in appetite regulation. (2) Semaglutide also controls blood sugar levels and has been shown to reduce hemoglobin A1c in diabetics. (3-5) Together these actions promote significant weight loss and improvements in weight-related complications for patients, as confirmed by extensive trials. (1,3-5)

Benefits of Semaglutide

• Weight Management: Semaglutide is highly effective in promoting substantial weight loss. One study showed that adults taking semaglutide for weight loss (in addition to lifestyle interventions) experienced an average of 14.9% weight loss compared to only 2.4% in the placebo group (1)

• Improvement in Coexisting Conditions: Semaglutide can also improve coexisting conditions related to obesity, such as type 2 diabetes or high blood pressure. It can even reduce the risk of developing cardiovascular complications in those with preexisting cardiovascular disease (6). 

Duration and Management of Semaglutide Side Effects

Semaglutide is the primary active ingredient in several well-known weight loss medications marketed as Ozempic®, Rybelsus, and Wegovy®. While semaglutide has helped thousands achieve their goals and transform their health, understanding and managing its side effects is essential for a smooth treatment process.

Common Side Effects

Gastrointestinal side effects are among the most commonly reported side effects for those just starting any GLP-1 medication, including semaglutide. (1,2,6,7) In a large clinical trial, 4.5% of participants in the semaglutide group discontinued treatment due to gastrointestinal side effects, vs <1% in the placebo group. (1)

• Nausea

• Vomiting

• Diarrhea

• Constipation

• Stomach pain

Duration of Side Effects

Semaglutide is usually administered once a week for 4 to 5 weeks before reaching "steady-state" or stable levels in the body. (6) Its half-life is approximately one week, which is a term used to describe the time it takes for the drug's active substance in your body to decrease by half. (6) Taking this into consideration, if you were to discontinue semaglutide entirely, it would take about 5 weeks for the drug to be completely cleared from your system. So if you are stopping semaglutide due to unpleasant side effects, it may take several weeks for your symptoms to completely resolve, given the medication's longer duration of action.

Rest assured that for most patients, side effects are usually mild to moderate in severity and, most importantly, temporary. (1) Gastrointestinal symptoms typically resolve with time as the body adjusts to the medication. (7) For most patients, these unpleasant symptoms worsen after starting the medication and immediately after each dose escalation, which occurs every couple of weeks during the first few months (7). These symptoms tend to resolve shortly after the user gets used to the increased dose. While these initial adjustments are the most common concern, many patients also wonder about the implications of staying on the medication for years. You can learn more about what 10-year data suggests about long-term GLP-1 safety to better understand the long-term outlook.

Management Tips:

• Start with a Low Dose: Gradually increasing the dosage allows your body to adapt slowly.(7)

• Stay Hydrated: Drinking plenty of fluids to stay hydrated can help mitigate some of the gastrointestinal side effects. (7) Furthermore, avoid stimulants such as caffeinated teas, coffee and soda that are dehydrating and can lead to more unpleasant gastrointestinal side effects. (7)

• Eat Smaller, More Frequent Meals: Eating small meals throughout the day will ensure you’re getting proper nutrition to fuel your body properly while on semaglutide. Furthermore, eating smaller meals throughout the day can help ease digestive processes during treatment. (7)

Navigating Treatment: Tips for Patients

• Open Communication: Regular discussions with your healthcare provider about any side effects you're experiencing are important to ensure you’re on the right plan.

• Follow a Healthy Diet: Integrating a balanced diet can complement the effects of semaglutide and improve overall well-being.

• Avoid triggers: For some patients, coffee, spicy, or fried foods may exacerbate unpleasant side effects such as diarrhea or heartburn after starting semaglutide. Try keeping a food diary and track which foods are causing these adverse effects. While it doesn’t mean you have to cut these triggers out entirely forever, it may be best to avoid them while you’re getting used to a new medication. 

When Side Effects Persist: Seeking Help

If side effects continue beyond the initial adjustment period or become severe, seek medical advice. Mochi Health provides 1-on-1 provider support from licensed physicians who specialize in obesity medicine, ensuring you’re supported every step of the way.

Mochi Health Support Includes:

• Customized weight loss plans

• Medications delivered to your door

• Direct messaging with providers for immediate guidance

• Comprehensive follow-ups to adjust treatment plans as necessary

Semaglutide presents a promising solution for weight management, but understanding how to manage its side effects is vital to a successful treatment outcome.

If you’re considering semaglutide for weight loss, Mochi Health offers an accessible and supportive path to achieve your goals. With personalized programs, expert guidance, and continuous support, overcoming the challenges of obesity treatment is within reach.

Explore your options and check your eligibility for Mochi Health’s weight loss program today. Your journey to a healthier, more joyful life is just a step away.

‍

This post was written by our team of health writers for informational purposes only and does not constitute medical advice. Always consult your doctor or healthcare provider for personalized guidance regarding your health.

‍

‍

This post was written by our team of health writers for informational purposes only and does not constitute medical advice. Always consult your doctor or healthcare provider for personalized guidance regarding your health. Ozempic®, Wegovy®, Mounjaro®, and Zepbound® and their delivery device are registered trademarks. Mochi Health is a telehealth clinic that offers prescriptions for these products by medical necessity only as determined by a licensed health provider.

Sources

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 384(11), 989–1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

2. Baggio, L. L., & Drucker, D. J. (2007). Biology of incretins: GLP-1 and GIP. Gastroenterology, 132(6), 2131–2157.. https://pubmed.ncbi.nlm.nih.gov/17498508/

3.  Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251–260. doi: 10.1016/S2213-8587(17)30013-X. https://pubmed.ncbi.nlm.nih.gov/28110911/

4. Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(5):355–366. doi: 10.1016/S2213-8587(17)30085-2. https://pubmed.ncbi.nlm.nih.gov/28344112/

5. Rodbard, H. W., Lingvay, I., Reed, J., de la Rosa, R., Rose, L., Sugimoto, D., Araki, E., Chu, P. L., Wijayasinghe, N., & Norwood, P. (2018). Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. The Journal of clinical endocrinology and metabolism, 103(6), 2291–2301. https://doi.org/10.1210/jc.2018-00070

6. Food and Drug Administration. Ozempic® (semaglutide) injection prescribing information, revised. 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209637s003lbl.pdf

7. Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., Górriz, J. L., & Rubio-Herrera, M. Á. (2022). Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. Journal of clinical medicine, 12(1), 145. https://doi.org/10.3390/jcm12010145